Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers

Bright,S.  A.; Byrne,A.  J.; Vandenberghe,E.; Browne,P.  V.; Mcelligott,A.  M.; Meegan,M.  J.; Williams,D.  C.

doi:10.3892/or.2019.7068

Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers

Authors:
- S. A. Bright
- A. J. Byrne
- E. Vandenberghe
- P. V. Browne
- A. M. Mcelligott
- M. J. Meegan
- D. C. Williams
View Affiliations

Affiliations: School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Republic of Ireland, School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Republic of Ireland, Discipline of Haematology, School of Medicine, Trinity Translational Medicine Institute, St. James's Hospital and Trinity College, Dublin 8, Republic of Ireland
Published online on: March 15, 2019 https://doi.org/10.3892/or.2019.7068
Pages: 3127-3136

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The nitrostyrene scaffold was previously identified as a lead target structure for the development of effective compounds targeting Burkitt's lymphoma. The present study aimed to develop these compounds further in haematological malignancies, including chronic lymphocytic leukaemia (CLL). Cellular viability, flow cytometry and lactate dehydrogenase assays, amongst others, were used to examine the effects of nitrostyrene compounds on CLL cells, including a cell line representing disease with poor prognosis (HG‑3) and in ex vivo CLL patient samples (n=14). The results demonstrated that two representative nitrostyrene compounds potently induced apoptosis in CLL cells. The pro‑apoptotic effects of the compounds were found to be reactive oxygen species and caspase‑dependent, and had minimal effects on the viability of normal donor peripheral blood mononuclear cells. Nitrostyrene compounds exhibited synergistic augmentation of apoptosis when combined with the phosphatidylinositol 3‑kinase inhibitor idelalisib and demonstrated potent toxicity in ex vivo CLL cells, including those co‑cultured with bone marrow stromal cells, making them more resistant to apoptosis (n=8). These compounds also demonstrated activity in samples from patients with poor prognostic indicators; unmutated immunoglobulin heavy chain genes, expression of CD38 and deletions in chromosomes 17p and 11q. These results suggest that this class of pharmaceutically active compounds offer potential in the treatment of CLL.

View Figures

View References

1	Nabhan C and Rosen ST: Chronic lymphocytic leukemia: A clinical review. JAMA. 312:2265–2276. 2014. View Article : Google Scholar : PubMed/NCBI
2	Puiggros A, Blanco G and Espinet B: Genetic abnormalities in chronic lymphocytic leukemia: Where we are and where we go. Biomed Res Int. 2014:4359832014. View Article : Google Scholar : PubMed/NCBI
3	Skarbnik AP and Faderl S: The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: Current evidence and controversies. Ther Adv Hematol. 8:99–105. 2017. View Article : Google Scholar : PubMed/NCBI
4	Montgomery JA and Hewson K: Nucleosides of 2-fluoroadenine. J Med Chem. 12:498–504. 1969. View Article : Google Scholar : PubMed/NCBI
5	Hallek M: Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 92:946–965. 2017. View Article : Google Scholar : PubMed/NCBI
6	Aalipour A and Advani RH: Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 5:121–133. 2014. View Article : Google Scholar : PubMed/NCBI
7	Shah A: New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab. Ther Clin Risk Manag. 11:1113–1122. 2015. View Article : Google Scholar : PubMed/NCBI
8	Shah A and Mangaonkar A: Idelalisib: A novel PI3Kδ inhibitor for chronic lymphocytic leukemia. Ann Pharmacother. 49:1162–1170. 2015. View Article : Google Scholar : PubMed/NCBI
9	Duman RS: Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 31:291–296. 2014. View Article : Google Scholar : PubMed/NCBI
10	Gold PW, Machado-Vieira R and Pavlatou MG: Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress. Neural Plast. 2015:5819762015. View Article : Google Scholar : PubMed/NCBI
11	Meredith EJ, Holder MJ, Chamba A, Challa A, Drake-Lee A, Bunce CM, Drayson MT, Pilkington G, Blakely RD, Dyer MJ, et al: The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics. FASEB J. 19:1187–1189. 2005. View Article : Google Scholar : PubMed/NCBI
12	Xia Z, Bergstrand A, DePierre JW and Nassberger L: The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 13:338–347. 1999. View Article : Google Scholar : PubMed/NCBI
13	Xia Z, DePierre JW and Nassberger L: Modulation of apoptosis induced by tricyclic antidepressants in human peripheral lymphocytes. J Biochem Mol Toxicol. 12:115–123. 1998. View Article : Google Scholar : PubMed/NCBI
14	Xia Z, Karlsson H, De Pierre JW and Nassberger L: Tricicylic antidepressants induce apoptosis in human T-lymphocytes. Int J Immunopharmacol. 19:645–654. 1997. View Article : Google Scholar : PubMed/NCBI
15	Cloonan SM, Drozgowska A, Fayne D and Williams DC: The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. 51:523–539. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cloonan SM and Williams DC: The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer. 128:1712–1723. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gandy MN, McIldowie M, Lewis K, Wasik AM, Salomonczyk D, Wagg K, Millar ZA, Tindiglia D, Huot P, Johnston T, et al: Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity. Med Chem Commun. 1:287–293. 2010. View Article : Google Scholar
18	McNamara YM, Bright SA, Byrne AJ, Cloonan SM, McCabe T, Williams DC and Meegan MJ: Synthesis and antiproliferative action of a novel series of maprotiline analogues. Eur J Med Chem. 71:333–353. 2014. View Article : Google Scholar : PubMed/NCBI
19	Cloonan SM, Keating JJ, Butler SG, Knox AJ, Jørgensen AM, Peters GH, Rai D, Corrigan D, Lloyd DG, Williams DC, et al: Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 44:4862–4888. 2009. View Article : Google Scholar : PubMed/NCBI
20	McNamara YM, Cloonan SM, Knox AJ, Keating JJ, Butler SG, Peters GH, Meegan MJ and Williams DC: Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents. Bioorg Med Chem. 19:1328–1348. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Slaga TJ and Hanausek M: Effects of desipramine on the cell cycle and apoptosis in Ca3/7 mouse skin squamous carcinoma cells. Int J Mol Med. 25:861–867. 2010.PubMed/NCBI
22	Parker KA, Glaysher S, Hurren J, Knight LA, McCormick D, Suovouri A, Amberger-Murphy V, Pilkington GJ and Cree IA: The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures. Anticancer Drugs. 23:65–69. 2012. View Article : Google Scholar : PubMed/NCBI
23	Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH and Shin SY: The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun. 413:311–317. 2011. View Article : Google Scholar : PubMed/NCBI
24	Lu T, Chou CT, Liang WZ, Yu CC, Chang HT, Kuo CC, Chen WC, Kuo DH, Ho CM, Shieh P and Jan CR: Effect of antidepressant doxepin on Ca²+ homeostasis and viability in PC3 human prostate cancer cells. Chin J Physiol. 58:178–187. 2015.PubMed/NCBI
25	Wang YY, Chen YK, Hsu YL, Chiu WC, Tsai CH, Hu SC, Hsieh PW and Yuan SF: Synthetic β-nitrostyrene derivative CYT-Rx20 as inhibitor of oral cancer cell proliferation and tumor growth through glutathione suppression and reactive oxygen species induction. Head Neck. 39:1055–1064. 2017. View Article : Google Scholar : PubMed/NCBI
26	Tsai CH, Hung AC, Chen YY, Chiu YW, Hsieh PW, Lee YC, Su YH, Chang PC, Hu SC and Yuan SF: 3′-hydroxy-4′-methoxy-β-methyl-β-nitrostyrene inhibits tumorigenesis in colorectal cancer cells through ROS-mediated DNA damage and mitochondrial dysfunction. Oncotarget. 8:18106–18117. 2017. View Article : Google Scholar : PubMed/NCBI
27	Messerschmitt PJ, Rettew AN, Schroeder NO, Brookover RE, Jakatdar AP, Getty PJ and Greenfield EM: Osteosarcoma phenotype is inhibited by 3,4-methylenedioxy-β-nitrostyrene. Sarcoma. 2012:4797122012. View Article : Google Scholar : PubMed/NCBI
28	Calgarotto AK, da Silva Pereira GJ, Bechara A, Paredes-Gamero EJ, Barbosa CM, Hirata H, de Souza Queiroz ML, Smaili SS and Bincoletto C: Autophagy inhibited Ehrlich ascitic tumor cells apoptosis induced by the nitrostyrene derivative compounds: Relationship with cytosolic calcium mobilization. Eur J Pharmacol. 678:6–14. 2012. View Article : Google Scholar : PubMed/NCBI
29	Pettit RK, Pettit GR, Hamel E, Hogan F, Moser BR, Wolf S, Pon S, Chapuis JC and Schmidt JM: E-Combretastatin and E-resveratrol structural modifications: Antimicrobial and cancer cell growth inhibitory β-E-nitrostyrenes. Bioorg Med Chem. 17:6606–6612. 2009. View Article : Google Scholar : PubMed/NCBI
30	He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y and Núñez G: 3,4-Methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 289:1142–1150. 2014. View Article : Google Scholar : PubMed/NCBI
31	Carter KC, Finnon YS, Daeid NN, Robson DC and Waddell R: The effect of nitrostyrene on cell proliferation and macrophage immune responses. Immunopharmacol Immunotoxicol. 24:187–197. 2002. View Article : Google Scholar : PubMed/NCBI
32	Jain N, Yada D, Shaik TB, Vasantha G, Reddy PS, Kalivendi SV and Sreedhar B: Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. Chem Med Chem. 6:859–868. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kim JH, Kim JH, Lee GE, Lee JE and Chung IK: Potent inhibition of human telomerase by nitrostyrene derivatives. Mol Pharmacol. 63:1117–1124. 2003. View Article : Google Scholar : PubMed/NCBI
34	Park J and Pei D: trans-Beta-nitrostyrene derivatives as slow-binding inhibitors of protein tyrosine phosphatases. Bioche-mistry. 43:15014–15021. 2004. View Article : Google Scholar
35	Villar JA, Lima FT, Veber CL, Oliveira AR, Calgarotto AK, Marangoni S and da Silva SL: Synthesis and evaluation of nitrostyrene derivative compounds, new snake venom phospholipase A2 inhibitors. Toxicon. 51:1467–1478. 2008. View Article : Google Scholar : PubMed/NCBI
36	Byrne AJ, Bright SA, Fayne D, McKeown JP, McCabe T, Twamley B, Williams C and Meegan MJ: Synthesis, antiproliferative and pro-apoptotic effects of nitrostyrenes and related compounds in Burkitt's lymphoma. Med Chem. 14:181–199. 2018. View Article : Google Scholar : PubMed/NCBI
37	Lanemo Myhrinder A, Hellqvist E, Sidorova E, Söderberg A, Baxendale H, Dahle C, Willander K, Tobin G, Bäckman E, Söderberg O, et al: A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 111:3838–3848. 2008. View Article : Google Scholar : PubMed/NCBI
38	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
39	McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, et al: The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res. 69:8366–8375. 2009. View Article : Google Scholar : PubMed/NCBI
40	Werner JM, Eger K and Jürgen Steinfelder H: Comparison of the rapid pro-apoptotic effect of trans-beta-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells. Apoptosis. 12:235–246. 2007. View Article : Google Scholar : PubMed/NCBI
41	Rahmani-Nezhad S, Safavi M, Pordeli M, Ardestani SK, Khosravani L, Pourshojaei Y, Mahdavi M, Emami S, Foroumadi A and Shafiee A: Synthesis, in vitro cytotoxicity and apoptosis inducing study of 2-aryl-3-nitro-2H-chromene derivatives as potent anti-breast cancer agents. Eur J Med Chem. 86:562–569. 2014. View Article : Google Scholar : PubMed/NCBI
42	Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ and Spurgeon SE: A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 5:908–915. 2014. View Article : Google Scholar : PubMed/NCBI
43	Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, Almasan A and his ED: The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br J Haematol. 163:72–80. 2013. View Article : Google Scholar : PubMed/NCBI
44	de Rooij MF, Kuil A, Kater AP, Kersten MJ, Pals ST and Spaargaren M: Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: A rationale for combination therapy. Blood. 125:2306–2309. 2015. View Article : Google Scholar : PubMed/NCBI
45	Panayiotidis P, Jones D, Ganeshaguru K, Foroni L and Hoffbrand AV: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92. 92:97–103. 1996. View Article : Google Scholar
46	Lagneaux L, Delforge A, De Bruyn C, Bernier M and Bron D: Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma. 35:445–453. 1999. View Article : Google Scholar : PubMed/NCBI
47	Bartels M, Calgarotto AK, Martens AC, Maso V, da Silva SL, Bierings MB, de Souza Queiroz ML and Coffer PJ: Differential effects of nitrostyrene derivatives on myelopoiesis involve regulation of C/EBPα and p38MAPK activity. PLoS One. 9:e905862014. View Article : Google Scholar : PubMed/NCBI